Arbutus Biopharma Corporation ABUS Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $18.01M-50.4% | $36.33M+38.2% | $26.29M-14.6% | $30.78M-71.8% | ||
| $73.46M-14.9% | $86.29M-13.5% | $99.72M-14.1% | $116.14M+152% | ||
| $0-100% | $2.41M+35.6% | $1.78M+31.4% | $1.35M+50.4% | ||
| $1.54M-32.7% | $2.28M-46.2% | $4.25M+47.8% | $2.87M-35.3% | ||
| $300K0.0% | $300K0.0% | $300K-50.0% | $600K— | ||
| $94.46M-25.8% | $127.32M-3.6% | $132.03M-12.6% | $151.14M-5.9% | ||
| $32K-99.0% | $3.31M-29.2% | $4.67M-7.8% | $5.07M-15.3% | ||
| $213K-98.4% | $13M+9.2% | $11.9M+10.2% | $10.8M+15.2% | ||
| $130K+282% | $34K— | $0-100% | $103K+68.9% | ||
| $0— | $0-100% | $6.28M-83.2% | $37.36M+4.7% | ||
| $94.62M-28.2% | $131.71M-8.8% | $144.4M-26.1% | $195.42M-4.4% | ||
| $1.17M-49.4% | $2.32M-28.1% | $3.22M-8.4% | $3.52M+10.9% | ||
| $547K+13.3% | $483K+13.6% | $425K+14.2% | $372K-2.9% | ||
| $6.01M-61.5% | $15.62M-30.5% | $22.49M-31.6% | $32.86M+193% | ||
| —— | —— | —— | —— | ||
| $199K-75.3% | $806K-40.0% | $1.34M-26.0% | $1.82M-18.6% | ||
| $18.04M-47.5% | $34.34M-10.5% | $38.38M-34.5% | $58.57M+67.1% | ||
| $1.42B+0.8% | $1.41B+4.5% | $1.35B+2.4% | $1.32B+2.5% | ||
| $83.32M+1.5% | $82.05M+1.0% | $81.27M+12.2% | $72.41M+10.6% | ||
| -$1.38B-2.5% | -$1.35B-5.5% | -$1.28B-6.1% | -$1.2B-6.1% | ||
| -$48.1M+0.1% | -$48.14M+0.6% | -$48.42M+4.1% | -$50.49M-4.5% | ||
| $76.58M-21.4% | $97.37M-8.2% | $106.02M-22.5% | $136.85M-19.2% | ||
| $94.62M-28.2% | $131.71M-8.8% | $144.4M-26.1% | $195.42M-4.4% | ||
| $73.38M-14.9% | $86.24M— | —— | —— | ||
| $73.46M-14.9% | $86.29M— | —— | —— | ||
| $73.46M-14.9% | $86.29M-13.5% | $99.72M-14.1% | $116.14M+152% | ||
| $130K+282% | $34K— | $0-100% | $103K+68.9% | ||
| $73.38M-14.9% | $86.24M— | —— | —— | ||
| —— | —— | —— | —— | ||
| $130K+282% | $34K— | $0-100% | $103K+68.9% | ||
| $130K+282% | $34K— | $0-100% | $103K+68.9% | ||
| $5.46M-27.8% | $7.56M-26.4% | $10.27M-35.9% | $16.03M+47.9% | ||
| $1.08M-7.6% | $1.16M+42.8% | $815K+59.2% | $512K-47.9% | ||
| $640K— | $0— | —— | —— | ||
| $8.4M-17.9% | $10.23M+34.5% | $7.6M+0.9% | $7.53M+42.1% | ||
| $746K-42.1% | $1.29M-27.1% | $1.77M-19.2% | $2.19M-16.3% | ||
| 192.5M+1.4% | 190M+11.8% | 169.9M+7.9% | 157.5M+8.6% | ||
| —— | —— | —— | —— | ||
| $1.42B+0.8% | $1.41B+4.5% | $1.35B+2.4% | $1.32B+2.5% | ||
| $87K+55.4% | $56K— | —— | —— | ||
| $0-100% | $6K— | —— | —— | ||
| 0-100% | 6-77.8% | 27-49.1% | 53— | ||
| $73.38M-14.9% | $86.24M— | —— | —— | ||
| $2.16M-36.4% | $3.39M+1.3% | $3.35M-10.2% | $3.73M-12.8% | ||
| $1.08M-7.6% | $1.16M+42.8% | $815K+59.2% | $512K-47.9% | ||
| $412K-40.4% | $691K-76.0% | $2.88M-65.1% | $8.26M+248% | ||
| $0-100% | $6K— | —— | —— | ||
| $87K+55.4% | $56K— | —— | —— | ||
| $73.38M-14.9% | $86.24M— | —— | —— | ||
| $73.46M-14.9% | $86.29M— | —— | —— | ||
| $10.22M-65.4% | $29.53M— | —— | —— | ||
| $192.53M+1.4% | $189.96M+11.8% | $169.87M+7.9% | $157.46M+8.6% | ||
| $192.53M+1.4% | $189.96M+11.8% | $169.87M+7.9% | $157.46M+8.6% | ||
| $0-100% | $6-77.8% | $27-49.1% | $53— | ||
| —— | —— | —— | —— | ||
| $3.44M-28.7% | $4.83M-30.5% | $6.95M-32.9% | $10.37M-36.4% | ||
| —— | —— | —— | —— | ||
| $640K— | $0— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Arbutus Biopharma Corporation's total assets?
- Arbutus Biopharma Corporation (ABUS) holds $277.2M in total assets, up 136.9% year over year.
- How much debt does Arbutus Biopharma Corporation have?
- Arbutus Biopharma Corporation carries $631.0K in total debt against $260.2M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Arbutus Biopharma Corporation have?
- Arbutus Biopharma Corporation holds $23.7M in cash and equivalents.
- Can Arbutus Biopharma Corporation cover its short-term obligations?
- Its current ratio is 54.26 — current assets exceed current liabilities.
- Where does Arbutus Biopharma Corporation's balance sheet data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
